MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes

[1]  D. Speiser,et al.  Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma , 2011, International journal of cancer.

[2]  D. Speiser,et al.  Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. , 2010, Seminars in immunology.

[3]  S. Jameson,et al.  Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire , 2009, Proceedings of the National Academy of Sciences.

[4]  Y. Togashi,et al.  Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells , 2009, British Journal of Cancer.

[5]  C. Bokemeyer,et al.  Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.

[6]  J. Greenman,et al.  Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer? , 2008, Head & neck.

[7]  R. Longhi,et al.  MAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells , 2007, Cancer Immunology, Immunotherapy.

[8]  Weifeng Chen,et al.  Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination , 2007, Cancer Immunology, Immunotherapy.

[9]  L. Bubendorf,et al.  Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer , 2007, International journal of cancer.

[10]  M. Young,et al.  Protective mechanisms of head and neck squamous cell carcinomas from immune assault , 2006, Head & neck.

[11]  B. Neyns,et al.  Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1 , 2006, Cancer Immunology, Immunotherapy.

[12]  F. Lemonnier,et al.  Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE , 2005, Clinical Cancer Research.

[13]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[14]  Yao-Tseng Chen,et al.  Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 , 2004, The Journal of Immunology.

[15]  C. Lamers,et al.  Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors , 2004, Journal of immunotherapy.

[16]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Angela Bachi,et al.  Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.

[18]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[19]  F. Lemonnier,et al.  Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy1 , 2002, The Journal of Immunology.

[20]  D. McNeel,et al.  Identification of T helper epitopes from prostatic acid phosphatase. , 2001, Cancer research.

[21]  E. Appella,et al.  Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. , 2001, Cancer research.

[22]  D. Speiser,et al.  Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma , 2000, The Journal of Immunology.

[23]  R. Steinman,et al.  Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[25]  G. Cornelis,et al.  A MAGE‐A4 peptide presented by HLA‐A2 is recognized by cytolytic T lymphocytes , 1999, European journal of immunology.

[26]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[27]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[28]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[29]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay , 1997 .

[30]  H. Rammensee,et al.  A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[32]  P. Guillaume,et al.  Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. , 2009, Cancer immunity.

[33]  P. Haaland,et al.  Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.

[34]  D. Speiser,et al.  Specific T Cells by MHC Class II Tetramers Epitopes and Ex Vivo Visualization of Melanoma Patients: Identification of New Melan-A/MART-1-Specific CD4 T Cells in , 2006 .

[35]  T. Whiteside,et al.  p53 as an immunotherapeutic target in head and neck cancer. , 2005, Advances in oto-rhino-laryngology.

[36]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[37]  B. Wollenberg,et al.  Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. , 1999, Archives of otolaryngology--head & neck surgery.

[38]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[39]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. , 1997, International journal of cancer.